Wire · founder news, decoded · opportunities
Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector
Sanofi wins FDA approval for Sarclisa Escena, the first cancer drug deliverable by on-body injector, matching efficacy to its IV formulation and using Enable Injections' CirCLIQ device. The subcutaneous option positions Sarclisa to compete more directly with J&J's Darzalex Faspro in multiple myeloma treatment.
This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.
The Wire takeaway
If you make delivery devices for large-volume injectables, Sanofi just proved the on-body injector is now table-stakes for competing oncology drugs—and J&J's five-year head start on subcutaneous Darzalex is eroding. Enable Injections owns this FDA playbook; your window to license or co-develop a competing platform is closing fast.
Read the full story at fiercepharma.com →
Topics: Digital Health · on-body-injector · subcutaneous-delivery · multiple-myeloma · device-pharma · regulatory-approval